China Pioneer Pharma Holdings Limited

1345.HK plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, 1345.HK stands at 2.5B. In comparison, 6160.HK has a market cap of 210.6B. Regarding current trading prices, 1345.HK is priced at HK$2.10, while 6160.HK trades at HK$145.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

1345.HK currently has a P/E ratio of 15.21, whereas 6160.HK's P/E ratio is -67.18. In terms of profitability, 1345.HK's ROE is +0.14%, compared to 6160.HK's ROE of -0.12%. Regarding short-term risk, 1345.HK is less volatile compared to 6160.HK. This indicates potentially lower risk in terms of short-term price fluctuations for 1345.HK.

1345.HK plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, 1345.HK stands at 2.5B. In comparison, 0241.HK has a market cap of 76.4B. Regarding current trading prices, 1345.HK is priced at HK$2.10, while 0241.HK trades at HK$4.65.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

1345.HK currently has a P/E ratio of 15.21, whereas 0241.HK's P/E ratio is 47.40. In terms of profitability, 1345.HK's ROE is +0.14%, compared to 0241.HK's ROE of +0.08%. Regarding short-term risk, 1345.HK is less volatile compared to 0241.HK. This indicates potentially lower risk in terms of short-term price fluctuations for 1345.HK.

1345.HK plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, 1345.HK stands at 2.5B. In comparison, 3613.HK has a market cap of 7.3B. Regarding current trading prices, 1345.HK is priced at HK$2.10, while 3613.HK trades at HK$8.86.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

1345.HK currently has a P/E ratio of 15.21, whereas 3613.HK's P/E ratio is 14.45. In terms of profitability, 1345.HK's ROE is +0.14%, compared to 3613.HK's ROE of +0.13%. Regarding short-term risk, 1345.HK is more volatile compared to 3613.HK. This indicates potentially higher risk in terms of short-term price fluctuations for 1345.HK.

1345.HK plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, 1345.HK stands at 2.5B. In comparison, 3390.HK has a market cap of 330.8M. Regarding current trading prices, 1345.HK is priced at HK$2.10, while 3390.HK trades at HK$0.37.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

1345.HK currently has a P/E ratio of 15.21, whereas 3390.HK's P/E ratio is 37.00. In terms of profitability, 1345.HK's ROE is +0.14%, compared to 3390.HK's ROE of +0.01%. Regarding short-term risk, 1345.HK is less volatile compared to 3390.HK. This indicates potentially lower risk in terms of short-term price fluctuations for 1345.HK.

1345.HK plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, 1345.HK stands at 2.5B. In comparison, 1110.HK has a market cap of 324.3M. Regarding current trading prices, 1345.HK is priced at HK$2.10, while 1110.HK trades at HK$0.57.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

1345.HK currently has a P/E ratio of 15.21, whereas 1110.HK's P/E ratio is 6.88. In terms of profitability, 1345.HK's ROE is +0.14%, compared to 1110.HK's ROE of +0.06%. Regarding short-term risk, 1345.HK is less volatile compared to 1110.HK. This indicates potentially lower risk in terms of short-term price fluctuations for 1345.HK.

1345.HK plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, 1345.HK stands at 2.5B. In comparison, 2211.HK has a market cap of 93.7M. Regarding current trading prices, 1345.HK is priced at HK$2.10, while 2211.HK trades at HK$1.11.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

1345.HK currently has a P/E ratio of 15.21, whereas 2211.HK's P/E ratio is 4.88. In terms of profitability, 1345.HK's ROE is +0.14%, compared to 2211.HK's ROE of +0.04%. Regarding short-term risk, 1345.HK is less volatile compared to 2211.HK. This indicates potentially lower risk in terms of short-term price fluctuations for 1345.HK.

1345.HK plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, 1345.HK stands at 2.5B. In comparison, 0348.HK has a market cap of 53.9M. Regarding current trading prices, 1345.HK is priced at HK$2.10, while 0348.HK trades at HK$0.07.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

1345.HK currently has a P/E ratio of 15.21, whereas 0348.HK's P/E ratio is -1.40. In terms of profitability, 1345.HK's ROE is +0.14%, compared to 0348.HK's ROE of +1.89%. Regarding short-term risk, 1345.HK is less volatile compared to 0348.HK. This indicates potentially lower risk in terms of short-term price fluctuations for 1345.HK.

1345.HK plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, 1345.HK stands at 2.5B. In comparison, 0574.HK has a market cap of 42.8M. Regarding current trading prices, 1345.HK is priced at HK$2.10, while 0574.HK trades at HK$0.03.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

1345.HK currently has a P/E ratio of 15.21, whereas 0574.HK's P/E ratio is -2.90. In terms of profitability, 1345.HK's ROE is +0.14%, compared to 0574.HK's ROE of -0.34%. Regarding short-term risk, 1345.HK is less volatile compared to 0574.HK. This indicates potentially lower risk in terms of short-term price fluctuations for 1345.HK.